GÃ©rard Siest

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3833002/publications.pdf

Version: 2024-02-01

261	7,631	57758	79698
papers	citations	44 h-index	73 g-index

273	273	273	7916
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	From DMDI â€œDrug Metabolism and Drug Interactionsâ€•to DMPT â€œDrug Metabolism and Personalized Therapyâ€• Drug Metabolism and Personalized Therapy, 2015, 30, 1.	0.6	2
2	Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. Clinical Chemistry and Laboratory Medicine, 2015, 53, 981-8.	2.3	18
3	Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. Drug Metabolism and Personalized Therapy, 2015, 30, 121-128.	0.6	9
4	Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers. Pharmacogenomics, 2015, 16, 459-469.	1.3	0
5	CYP 2C19 and UDP-glucuronosyltransferases not only for drugs but also for endobiotics. Drug Metabolism and Drug Interactions, 2014, 29, 207-209.	0.3	0
6	Conference Scene: Pharmacogenomics: from cell to clinic (Part 2). Pharmacogenomics, 2014, 15, 739-744.	1.3	1
7	Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids. Drug Metabolism Reviews, 2014, 46, 33-56.	3.6	24
8	Systems medicine, stratified medicine, personalized medicine but not precision medicine. Drug Metabolism and Drug Interactions, 2014, 29, 1-2.	0.3	7
9	Human cytochrome P450 epoxygenases: Variability in expression and role in inflammation-related disorders. , 2014, 144, 134-161.		74
10	Epistatic study reveals two genetic interactions in blood pressure regulation. BMC Medical Genetics, 2013, 14, 2.	2.1	13
11	The theory of reference values: an unfinished symphony. Clinical Chemistry and Laboratory Medicine, 2013, 51, 47-64.	2.3	88
12	Dairy product consumption, calcium intakes, and metabolic syndromeâ€“related factors over 5 years in the STANISLAS study. Nutrition, 2013, 29, 519-524.	2.4	60
13	Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285. International Journal of Cardiology, 2013, 168, 3057-3058.	1.7	2
14	A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. Journal of Lipid Research, 2013, 54, 535-541.	4.2	28
15	Pharmacogenomics: from cell to clinic. Drug Metabolism and Drug Interactions, 2013, 28, 133.	0.3	0
16	Clinical Chemistry and Laboratory Medicine: progress and new challenges for our 50-year-old journal. Clinical Chemistry and Laboratory Medicine, 2013, 51, 5-7.	2.3	4
17	Pharmacogenomics and Theranostics in Practice: A summary of the Euromedlab-ESPT (The European) Tj ETQq1 1 0.784314 rgBT /Ove the International Federation of Clinical Chemistry and Laboratory Medicine, 2013, 24, 85-9.	0.7	2
18	Maintain the goals of Drug Metabolism and Drug Interactions. Drug Metabolism and Drug Interactions, 2012, 27, 183-4.	0.3	0

#	Article	IF	Citations
19	Alcohol Consumption, Beverage Preference, and Diet in Middle-Aged Men from the STANISLAS Study. Journal of Nutrition and Metabolism, 2012, 2012, 1-6.	1.8	21
20	Drug Metabolism and Drug Interactions and the European Society of Pharmacogenomics and Theranostics. Drug Metabolism and Drug Interactions, 2012, 27, 61-61.	0.3	0
21	Clinical interest of point-of-care pharmacogenomic testing: clopidogrel behind warfarin. Pharmacogenomics, 2012, 13, 1215-1218.	1.3	5
22	Clinical necessity of partitioning of human plasma haptoglobin reference intervals by recently-discovered rs2000999. Clinica Chimica Acta, 2012, 413, 1618-1624.	1.1	15
23	High Prevalence of Metabolic Syndrome in Iran in Comparison with France: What Are the Components That Explain This?. Metabolic Syndrome and Related Disorders, 2012, 10, 181-188.	1.3	51
24	A Genome-Wide Association Study Identifies rs2000999 as a Strong Genetic Determinant of Circulating Haptoglobin Levels. PLoS ONE, 2012, 7, e32327.	2.5	34
25	Functional genomics towards personalized healthcare and systems medicine. Personalized Medicine, 2011, 8, 227-242.	1.5	1
26	Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy. Pharmacogenomics, 2011, 12, 681-691.	1.3	4
27	Pharmacogenomics and drug interactions. A specific journal. Drug Metabolism and Drug Interactions, 2011, 26, 1.	0.3	0
28	Identification of cis - and trans -Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels. Circulation Research, 2011, 109, 554-563.	4.5	72
29	Biological and genetic factors associated with ABCB1 and pregnane-X-receptor expressions in peripheral blood mononuclear cells in the STANISLAS cohort. Drug Metabolism and Drug Interactions, 2011, 26, 27-32.	0.3	3
30	Expression of inflammatory molecules and associations with BMI in children. European Journal of Clinical Investigation, 2010, 40, 388-392.	3.4	23
31	Sexâ€dependent Associations of Leptin With Metabolic Syndromeâ€"related Variables: The Stanislas Study. Obesity, 2010, 18, 196-201.	3.0	24
32	Metabolic syndrome-related composite factors over 5years in the STANISLAS Family Study: Genetic heritability and common environmental influences. Clinica Chimica Acta, 2010, 411, 833-839.	1.1	14
33	Visfatin: The Link Between Inflammation and Childhood Obesity. Diabetes Care, 2009, 32, e71-e71.	8.6	20
34	Increasing laboratory medicine activities in China: research and publications. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1209.	2.3	1
35	Personalized therapy and pharmacogenomics: future perspective. Pharmacogenomics, 2009, 10, 927-930.	1.3	9
36	Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 2. ApoE and apoC-III relations in triglyceride clearance. Molecular and Cellular Biochemistry, 2009, 325, 25-40.	3.1	3

#	Article	IF	Citations
37	Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 1. ApoE distribution between lipoproteins. Molecular and Cellular Biochemistry, 2009, 325, 41-51.	3.1	3
38	Genetic profiling of human cell lines used as in vitro model to study cardiovascular pathophysiology and pharmacotoxicology. Cell Biology and Toxicology, 2009, 25, 561-571.	5.3	6
39	Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. Clinica Chimica Acta, 2009, 403, 198-202.	1.1	23
40	Adipokine expression in adipose tissue and in peripheral blood mononuclear cells in children. Clinica Chimica Acta, 2009, 410, 85-89.	1.1	7
41	Human formyl peptide receptor 1 (FPR1) c.32C>T SNP is associated with decreased soluble E-selectin levels. Pharmacogenomics, 2009, 10, 951-959.	1.3	8
42	Systems biology and personalized prevention. Personalized Medicine, 2009, 6, 265-268.	1.5	0
43	Parental precocious influences on offspring cardiovascular risk markers: an exploratory study in the STANISLAS Cohort. Personalized Medicine, 2009, 6, 343-352.	1.5	0
44	Functional genomics towards personalized healthcare. Personalized Medicine, 2009, 6, 19-32.	1.5	3
45	Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps. Current Drug Metabolism, 2009, 10, 410-419.	1.2	5
46	Statins as effectors of key activities involved in apoE-dependent VLDL metabolism: Review and hypothesis. Vascular Pharmacology, 2008, 48, 70-75.	2.1	10
47	Pharmacogenomics and Cardiovascular Drugs. Methods in Pharmacology and Toxicology, 2008, , 413-446.	0.2	0
48	Transcription Factor and Drug-Metabolizing Enzyme Gene Expression in Lymphocytes from Healthy Human Subjects. Drug Metabolism and Disposition, 2008, 36, 182-189.	3.3	80
49	Pharmacy-based laboratory services: past or future and risk or opportunity?. Clinical Chemistry and Laboratory Medicine, 2008, 46, 435-6.	2.3	6
50	The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases. Clinical Chemistry and Laboratory Medicine, 2008, 46, 733-47.	2.3	50
51	CCLM: Evolving to meet the needs of today's laboratory professionals and scientists. Clinical Chemistry and Laboratory Medicine, 2008, 46, 883-4.	2.3	7
52	Genetic profiling in healthy subjects from the Stanislas cohort based on 24 polymorphisms: effects on biological variables. Clinical Chemistry and Laboratory Medicine, 2008, 46, 64-72.	2.3	1
53	From human genetic variations to prediction of risks and responses to drugs and the environment. Clinical Chemistry and Laboratory Medicine, 2007, 45, 277-8.	2.3	0
54	Association of classical and related inflammatory markers with high-sensitivity C-reactive protein in healthy individuals: results from the Stanislas cohort. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1339-46.	2.3	11

#	Article	IF	Citations
55	Meeting Report: From human genetic variations to prediction of risks and responses to drugs and the environment. Clinical Chemistry and Laboratory Medicine, 2007, 45, .	2.3	0
56	Effect of HMGCoA Reductase Inhibitors on Cytochrome P450 Expression in Endothelial Cell Line. Journal of Cardiovascular Pharmacology, 2007, 49, 306-315.	1.9	23
57	Enzymes and pharmacogenetics of cardiovascular drugs. Clinica Chimica Acta, 2007, 381, 26-31.	1.1	40
58	Analysis of the effect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. Atherosclerosis, 2007, 191, 369-376.	0.8	13
59	Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine. Personalized Medicine, 2007, 4, 393-412.	1.5	4
60	The Lipoprotein Lipase Serine 447 Stop Polymorphism Is Associated With Altered Serum Carotenoid Concentrations in the Stanislas Family Study. Journal of the American College of Nutrition, 2007, 26, 655-662.	1.8	29
61	From human genetic variations to prediction of risks and responses to drugs and the environment. Personalized Medicine, 2007, 4, 95-104.	1.5	3
62	Metrological sharp shooting for plasma proteins and peptides: The need for reference materials for accurate measurements in clinical proteomics and in vitro diagnostics to generate reliable results. Proteomics - Clinical Applications, 2007, 1, 1016-1035.	1.6	10
63	Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundamental and Clinical Pharmacology, 2007, 21, 411-418.	1.9	40
64	Compared Effect of Immunosuppressive Drugs Cyclosporine A and Rapamycin on Cholesterol Homeostasis Key Enzymes CYP27A1 and HMG-CoA Reductase. Basic and Clinical Pharmacology and Toxicology, 2007, 100, 392-397.	2.5	37
65	HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. , 2006, , 63-89.		0
66	Genetic and environmental contributions to serum ascorbic acid concentrations: the Stanislas Family Study. British Journal of Nutrition, 2006, 96, 1013-1020.	2.3	2
67	Interaction between CYP1A1 T3801C and AHR G1661A polymorphisms according to smoking status on blood pressure in the Stanislas cohort. Journal of Hypertension, 2006, 24, 2199-2205.	0.5	21
68	The structure of human apolipoprotein E2, E3 and E4 in solution. Biophysical Chemistry, 2006, 119, 158-169.	2.8	17
69	The structure of human apolipoprotein E2, E3 and E4 in solution. 2. Multidomain organization correlates with the stability of apoE structure. Biophysical Chemistry, 2006, 119, 170-185.	2.8	26
70	Natriuretic peptides and evidence-based quality specifications. Clinical Chemistry and Laboratory Medicine, 2006, 44, 355-7.	2.3	1
71	CCLM: Expanding the science worldwide. Clinical Chemistry and Laboratory Medicine, 2006, 44, .	2.3	0
72	Genetic determinants of blood pressure regulation. Journal of Hypertension, 2005, 23, 2127-2143.	0.5	94

#	Article	IF	Citations
73	Biological variations, genetic polymorphisms and familial resemblance of TNF-Î± and IL-6 concentrations: STANISLAS cohort. European Journal of Human Genetics, 2005, 13, 109-117.	2.8	70
74	Pharmacogenomics and cardiovascular drugs: Need for integrated biological system with phenotypes and proteomic markers. European Journal of Pharmacology, 2005, 527, 1-22.	3.5	32
75	Polymorphism of the 5-HT2A receptor gene and food intakes in children and adolescents: the Stanislas Family Study. American Journal of Clinical Nutrition, 2005, 82, 467-470.	4.7	12
76	Genetic and environmental contributions to serum retinol and Î±-tocopherol concentrations: the Stanislas Family Study. American Journal of Clinical Nutrition, 2005, 81, 1034-1044.	4.7	27
77	The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype. Biological Chemistry, 2005, 386, 441-52.	2.5	11
78	A Prospective Study on the Prevalence of Metabolic Syndrome Among Healthy French Families: Two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-Â) are revealed in the offspring of parents with metabolic syndrome. Diabetes Care, 2005, 28, 675-682.	8.6	32
79	Cardiovascular risk-associated allele frequencies for 15 genes in healthy elderly French and Chinese. Clinical Chemistry and Laboratory Medicine, 2005, 43, 817-22.	2.3	6
80	Second Santorini Conference â€œFrom Human Genetic Variations to Prediction of Risks and Responses to Drugs and to the Environmentâ€• Clinical Chemistry and Laboratory Medicine, 2005, 43, .	2.3	0
81	Age- and sex-related reference values for serum insulin concentration and its biological determinants in a French healthy population. The STANISLAS cohort. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1140-9.	2.3	12
82	CYTOCHROME P-450-MEDIATED DIFFERENTIAL OXIDATIVE MODIFICATION OF PROTEINS: ALBUMIN, APOLIPOPROTEIN E, AND CYP2E1 AS TARGETS. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2004, 67, 2061-2071.	2.3	10
83	Phenotypic sensitivity to activated protein C in healthy families: importance of genetic components and environmental factors. British Journal of Haematology, 2004, 126, 392-397.	2.5	7
84	Genetic influences on blood pressure within the Stanislas Cohort. Journal of Hypertension, 2004, 22, 297-304.	0.5	8
85	Synthesis and in Vitro Antioxidant Activity of Glycyrrhetinic Acid Derivatives Tested with the Cytochrome P450/NADPH System. Chemical and Pharmaceutical Bulletin, 2004, 52, 1436-1439.	1.3	28
86	Study of reference values and biological variation: a necessity and a model for Preventive Medicine Centers. Clinical Chemistry and Laboratory Medicine, 2004, 42, 810-6.	2.3	16
87	Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype. Vascular Pharmacology, 2003, 40, 237-245.	2.1	6
88	Homo- and hetero-complexes of exchangeable apolipoproteins in solution and in lipid-bound form. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2003, 59, 1127-1137.	3.9	9
89	Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome. Atherosclerosis, 2003, 167, 223-230.	0.8	42
90	IL-6, TNF-Î± and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis, 2003, 170, 277-283.	0.8	137

#	Article	IF	Citations
91	Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study. Neuroscience Letters, 2003, 349, 95-98.	2.1	35
92	Charge-based heterogeneity of human plasma lipoproteins at hypertriglyceridemia: capillary isotachophoresis study. International Journal of Biochemistry and Cell Biology, 2003, 35, 530-543.	2.8	10
93	Effect of six candidate genes on early aging in a French population. Aging Clinical and Experimental Research, 2003, 15, 111-116.	2.9	14
94	Biological and genetic determinants of serum apoC-III concentration: reference limits from the Stanislas Cohort. Journal of Lipid Research, 2003, 44, 430-436.	4.2	27
95	Pharmacogenomics of Drugs Affecting the Cardiovascular System. Clinical Chemistry and Laboratory Medicine, 2003, 41, 590-9.	2.3	14
96	Family study of the relationship between height and cardiovascular risk factors in the STANISLAS cohort. International Journal of Epidemiology, 2003, 32, 607-614.	1.9	22
97	Serum Total Antioxidant Status, Erythrocyte Superoxide Dismutase and Whole-Blood Glutathione Peroxidase Activities in the Stanislas Cohort: Influencing Factors and Reference Intervals. Clinical Chemistry and Laboratory Medicine, 2003, 41, 209-15.	2.3	33
98	PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study. Clinical Chemistry and Laboratory Medicine, 2003, 41, 535-40.	2.3	25
99	Family Studies: Their Role in the Evaluation of Genetic Cardiovascular Risk Factors. Clinical Chemistry and Laboratory Medicine, 2002, 40, 1085-96.	2.3	14
100	Serum Total Antioxidant Status Is Higher in Postmenopausal Women and after Estrogen Replacement Therapy. Clinical Chemistry and Laboratory Medicine, 2002, 40, 850-2.	2.3	2
101	Growing Significance of Myeloperoxidase in Non-infectious Diseases. Clinical Chemistry and Laboratory Medicine, 2002, 40, 2-8.	2.3	78
102	Lipid Free Apolipoprotein E Binds to the Class B Type I Scavenger Receptor I (SR-BI) and Enhances Cholesteryl Ester Uptake from Lipoproteins. Journal of Biological Chemistry, 2002, 277, 36092-36099.	3.4	50
103	Î³-Glutamyltranspeptidase-Dependent Metabolism of 4-Hydroxynonenalâ€“Glutathione Conjugate. Archives of Biochemistry and Biophysics, 2002, 397, 18-27.	3.0	31
104	Apolipoprotein E Activates Akt Pathway in Neuro-2a in an Isoform-Specific Manner. Biochemical and Biophysical Research Communications, 2002, 292, 83-87.	2.1	28
105	An Isocratic Liquid Chromatographic Method with Diode-Array Detection for the Simultaneous Determination of Â-Tocopherol, Retinol, and Five Carotenoids in Human Serum. Journal of Chromatographic Science, 2002, 40, 69-76.	1.4	73
106	Differential Role of CYP2E1 Binders and Isoniazid on CYP2E1 Protein Modification in NADPH-dependent Microsomal Oxidative Reactions: Free Radical Scavenging Ability of Isoniazid. Free Radical Research, 2002, 36, 893-903.	3.3	23
107	Rapid spectrophotometric method for serum glutathione S-transferases activity. Clinica Chimica Acta, 2002, 326, 131-142.	1.1	81
108	Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1583, 99-107.	2.4	21

#	Article	IF	Citations
109	Human Apolipoprotein E concentration in response to diseases and therapeutic treatments. Drug Development Research, 2002, 56, 95-110.	2.9	4
110	Extension of variance components approach to incorporate temporal trends and longitudinal pedigree data analysis. Genetic Epidemiology, 2002, 22, 221-232.	1.3	40
111	The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. European Journal of Human Genetics, 2002, 10, 841-850.	2.8	75
112	Changes in Serum Apolipoprotein and Lipoprotein Profile After Alcohol Withdrawal: Effect of Apolipoprotein E Polymorphism. Alcoholism: Clinical and Experimental Research, 2002, 26, 501-508.	2.4	7
113	Changes in Serum Apolipoprotein and Lipoprotein Profile After Alcohol Withdrawal: Effect of Apolipoprotein E Polymorphism. Alcoholism: Clinical and Experimental Research, 2002, 26, 501-508.	2.4	2
114	Increased protein glycation in cerebrospinal fluid of Alzheimerâ€™s disease 2 2Abbreviations: AD, Alzheimerâ€™s disease; AGEs, advanced glycation end products; apo, apolipoprotein; BSA, bovine serum albumin; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate buffer saline.. Neurobiology of Aging, 2001, 22, 397-402.	3.1	148
115	Control of apolipoprotein E secretion in the human hepatoma cell line KYN-2. Cell Biochemistry and Function, 2001, 19, 51-58.	2.9	11
116	Proteinâ€“lipid interactions in reconstituted high density lipoproteins: apolipoprotein and cholesterol influence. Chemistry and Physics of Lipids, 2001, 113, 67-82.	3.2	11
117	Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. European Journal of Human Genetics, 2001, 9, 780-786.	2.8	86
118	Soluble Transferrin Receptor (sTfR): Biological Variations and Reference Limits. Clinical Chemistry and Laboratory Medicine, 2001, 39, 1162-8.	2.3	18
119	Determination of Serum Cystatin C: Biological Variation and Reference Values. Clinical Chemistry and Laboratory Medicine, 2001, 39, 850-7.	2.3	131
120	Candidate Gene Polymorphism in Cardiovascular Disease: A Comparative Study of Frequencies between a French and an Italian Population. Clinical Chemistry and Laboratory Medicine, 2001, 39, 146-54.	2.3	14
121	High Sensitivity C-Reactive Protein (CRP) Reference Intervals in the Elderly. Clinical Chemistry and Laboratory Medicine, 2001, 39, 1169-70.	2.3	12
122	Lipoprotein lipase (C/G)447 polymorphism and blood pressure in the Stanislas Cohort. Journal of Hypertension, 2000, 18, 1775-1781.	0.5	24
123	Effects of pro-inflammatory cytokines on apolipoprotein E secretion by a human astrocytoma cell line (CCF-STTG1). , 2000, 18, 9-16.		25
124	Evidence for the pro-oxidant effect of Î³-glutamyltranspeptidaseâ€“related enzyme11H. Aberkane and J. F. Salazar contributed equally to this work.. Free Radical Biology and Medicine, 2000, 29, 825-833.	2.9	35
125	Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Radical Biology and Medicine, 2000, 28, 129-140.	2.9	75
126	Familial Studies on the Genetics of Cardiovascular Diseases: the Stanislas Cohort. Clinical Chemistry and Laboratory Medicine, 2000, 38, 827-32.	2.3	15

#	Article	IF	Citations
127	Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study. Clinical Chemistry and Laboratory Medicine, 2000, 38, 721-730.	2.3	70
128	Apolipoprotein E Polymorphisms and Concentration in Chronic Diseases and Drug Responses. Clinical Chemistry and Laboratory Medicine, 2000, 38, 841-852.	2.3	58
129	Effect of Short- and Long-Term Storage on Human Serum and Recombinant Apolipoprotein E Concentration. Clinical Chemistry and Laboratory Medicine, 2000, 38, 525-8.	2.3	6
130	Associations of Apolipoprotein E Concentration and Polymorphism with Lipids and Apolipoprotein Levels in Chinese from Beijing and Shanghai. Clinical Chemistry and Laboratory Medicine, 2000, 38, 655-9.	2.3	11
131	Heparin specifically inhibits binding of apolipoprotein E to amyloid Î²-peptide. Neuroscience Letters, 2000, 280, 131-134.	2.1	20
132	Effect of apolipoprotein E on cell viability in a human neuroblastoma cell line: influence of oxidation and lipid-association. Neuroscience Letters, 2000, 285, 173-176.	2.1	6
133	Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1484, 14-28.	2.4	19
134	Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1484, 29-40.	2.4	11
135	High Sensitivity C-Reactive Protein: Biological Variations and Reference Limits. Clinical Chemistry and Laboratory Medicine, 2000, 38, 1003-1011.	2.3	74
136	Wine, Beer, and Mortality in Middle-aged Men From Eastern France. Archives of Internal Medicine, 1999, 159, 1865.	3.8	176
137	Capillary electrophoretic analysis of recombinant human apolipoprotein E. Journal of Chromatography A, 1999, 853, 237-241.	3.7	7
138	Bivariate familial correlation analysis of quantitative traits by use of estimating equations: Application to a familial analysis of the insulin resistance syndrome. , 1999, 16, 69-83.		19
139	Simultaneous measurement of reactive oxygen species and reduced glutathione using capillary electrophoresis and laser-induced fluorescence detection in cultured cell lines. Electrophoresis, 1999, 20, 2938-2944.	2.4	48
140	Glycation of apolipoprotein E impairs its binding to heparin: identification of the major glycation site. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1999, 1454, 296-308.	3.8	34
141	Kinetics of apolipoprotein E isoforms-binding to the major glycosaminoglycans of the extracellular matrix. FEBS Letters, 1999, 459, 353-357.	2.8	25
142	A Multilocus Genotyping Assay for Candidate Markers of Cardiovascular Disease Risk. Genome Research, 1999, 9, 936-949.	5.5	193
143	Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochemical Journal, 1999, 338, 281.	3.7	11
144	Characterization and quantification of serum lipoprotein subfractions by capillary isotachophoresis: relationships with lipid, apolipoprotein, and lipoprotein levels. Journal of Lipid Research, 1999, 40, 2125-2133.	4.2	20

#	Article	IF	Citations
145	Apolipoprotein AIV codon 360 mutation increases with human aging and is not associated with Alzheimer's disease. Neuroscience Letters, 1998, 242, 117-119.	2.1	17
146	Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Letters, 1998, 425, 225-228.	2.8	97
147	An intronic promoter controls the expression of truncated human Î³-glutamyltransferase mRNAs1. FEBS Letters, 1998, 434, 51-56.	2.8	10
148	Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis, 1998, 140, 89-95.	0.8	51
149	Association of Apolipoprotein E Polymorphism and Concentration with Serum Lipids and Apo-lipoprotein Level in the Chinese fromShanghai. Clinical Chemistry and Laboratory Medicine, 1998, 36, 615-619.	2.3	10
150	Human Genomics: The Basis of the Medicine of Tomorrow. Recent Progress in Molecular Biology Technology. First IFCC-Roche Conference â€“ Singapore, 15â€“18 March 1998. Clinical Chemistry and Laboratory Medicine, 1998, 36, .	2.3	0
151	Objectives, Design and Recruitment of a Familial and Longitudinal Cohort for Studying Gene-Environment Interactions in the Field of Cardiovascular Risk: The Stanislas Cohort. Clinical Chemistry and Laboratory Medicine, 1998, 36, 35-42.	2.3	130
152	A Multilocus Genotyping Assay for Cardiovascular Disease. Clinical Chemistry and Laboratory Medicine, 1998, 36, 561-6.	2.3	45
153	Biological Effects of Eleven Combined Oral Contraceptives on Serum Triglycerides, Î³-Glutamyltransferase, Alkaline Phosphatase, Bilirubin and other Biochemical Variables. Clinical Chemistry and Laboratory Medicine, 1998, 36, 871-8.	2.3	25
154	Intimaâ€“media thickness and diameter of carotid and femoral arteries in children, adolescents and adults from the Stanislas cohort. Journal of Hypertension, 1998, 16, 1593-1602.	0.5	170
155	Differential Susceptibility of Human Apolipoprotein E Isoforms to Oxidation and Consequences on their Interaction with Phospholipids. Advances in Behavioral Biology, 1998, , 31-38.	0.2	0
156	Gene transfer technologies for the production of enzyme and protein reference materials. Clinica Chimica Acta, 1997, 257, 3-23.	1.1	3
157	Low and very low density lipoprotein composition and resistance to copper-induced oxidation are not notably modified in smokers. Clinica Chimica Acta, 1997, 265, 1-12.	1.1	18
158	Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal. Clinica Chimica Acta, 1996, 253, 127-143.	1.1	10
159	Interaction between human amphipathic apolipoproteins and amyloid Î²-peptide: surface plasmon resonance studies. FEBS Letters, 1996, 383, 9-12.	2.8	34
160	Cloning and expression of a novel type (III) of human Î³-glutamyltransferase truncated mRNA. FEBS Letters, 1996, 394, 258-262.	2.8	6
161	Single-Step Purification of Two Functional Human Apolipoprotein E Variants Hyperexpressed inEscherichia coli. Protein Expression and Purification, 1996, 7, 407-414.	1.3	12
162	Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels. , 1996, 13, 179-192.		29

#	Article	IF	Citations
163	Reference Limits of Apolipoprotein A-I and Apolipoprotein B Using an IFCC Standardized Immunonephelometric Method. Clinical Chemistry and Laboratory Medicine, 1995, 33, 337-42.	2.3	9
164	Glucuronidation in the caco-2 human intestinal cell line: Induction of UDP-glucuronosyltransferase 1âˆ—6. Biochemical Pharmacology, 1995, 50, 557-561.	4.4	33
165	Gamma-glutamyltransferase expression during all-transretinoic acid-induced differentiation of hematopoietic cell lines. FEBS Letters, 1995, 369, 183-186.	2.8	9
166	Dextromethorphan O-demethylase activity in rat brain microsomes. Neuroscience Letters, 1995, 187, 65-68.	2.1	24
167	Segregation analysis and variance components analysis of bone mineral density in healthy families. Journal of Bone and Mineral Research, 1995, 10, 2017-2022.	2.8	293
168	Heterogeneity of Hepatic Microsomal UDP-Glucuronosyltransferase(s) Activities: A New Kinetic Approach for the Study of Induction and Specificity. Journal of Pharmaceutical Sciences, 1994, 83, 591-596.	3.3	3
169	Sources of variability of human plasma apolipoprotein A-IV levels and relationships with lipid metabolism. Genetic Epidemiology, 1994, 11, 101-114.	1.3	11
170	Molecular and functional characterization of recombinant human gamma-glutamyltransferase. Coupling of its activity to glutathione levels in V79 cells. FEBS Journal, 1994, 222, 1009-1016.	0.2	12
171	Glycosylation of gamma-glutamyltransferase is modified by ethanol in H5â€“6 hepatoma cell line. Clinica Chimica Acta, 1994, 225, 1-15.	1.1	3
172	Localization of a regulatory region on the 5â€²-untranslated region of human hepatoma HepG2 Î³-glutamyltransferase mRNA and response to dexamethasone and antisense oligonucleotide treatment. FEBS Letters, 1994, 356, 307-310.	2.8	5
173	Expression of the human UDP-glucuronosyltransferase UGT116 inEscherichia coli. FEBS Letters, 1994, 339, 195-199.	2.8	11
174	Induction and immunological characterization of the uridine diphosphate-glucuronosyltransferase conjugating 1-naphthol in the rat choroid plexus. Neuroscience Letters, 1994, 175, 37-40.	2.1	23
175	DNA polymorphisms of human apolipoprotein Aâ€IV gene: frequency and effects on lipid, lipoprotein and apolipoprotein levels in a French population. Clinical Genetics, 1994, 46, 248-254.	2.0	29
176	Rapid liquid chromatographic assay of glutathione in cultured cells. Biomedical Chromatography, 1993, 7, 86-89.	1.7	36
177	Repression of cytochrome P450 by cytokines: IL-1? counteracts clofibric acid induction of CYP4A in cultured fetal rat hepatocytes. Cell Biology and Toxicology, 1993, 9, 307-313.	5.3	20
178	Establishment of a V79 transfected cell line highly producing recombinant human Î³-glutamyltransferase. Toxicology, 1993, 82, 151-167.	4.2	2
179	Malondialdehyde adducts to, and fragmentation of, apolipoprotein B from human plasma. Clinica Chimica Acta, 1993, 218, 39-46.	1.1	19
180	The 5' untranslated region of the human Î³-glutamyl transferase mRNA contains a tissue-specific active translational enhancer. FEBS Letters, 1993, 332, 88-92.	2.8	18

#	Article	IF	Citations
181	Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. Biochemical Pharmacology, 1993, 45, 647-658.	4.4	105
182	Differential effects of human recombinant interleukin-1Î² and dexamethasone on hepatic drug-metabolizing enzymes in male and female rats. Biochemical Pharmacology, 1993, 45, 2269-2277.	4.4	40
183	Peroxisome proliferators as inducers and substrates of UDP-glucuronosyltransferases. Biology of the Cell, 1993, 77, 13-16.	2.0	9
184	Heterogeneity of hepatic UDP-Glucuronosyltransferase activities: Investigations of isoenzymes involved in p-nitrophenol glucuronidation. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 1993, 106, 241-248.	0.5	9
185	Glucuronidation of 3â€²-azido-3â€²-deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1992, 1139, 20-24.	3.8	23
186	Length and sequence variation in the apolipoprotein B intron 20 Alu repeat. Genomics, 1992, 14, 449-454.	2.9	7
187	Allele frequency distribution of the (TG)n(AG)m microsatellite in the apolipoprotein C-II gene. Genomics, 1992, 12, 63-68.	2.9	28
188	Î³-Glutamyltransferase: Nucleotide sequence of the human pancreatic cDNA. Biochemical Pharmacology, 1992, 43, 2527-2533.	4.4	65
189	Enzyme induction by drugs and toxins. Clinica Chimica Acta, 1992, 209, 109-121.	1.1	29
190	Viral Immortalization and Phenotypic Characterization of a Rat Hepatocyte Cell Line. Cellular Physiology and Biochemistry, 1992, 2, 349-358.	1.6	0
191	Age-related variations of enzymatic defenses against free radicals and peroxides. , 1992, 62, 359-367.		18
192	Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Research Reviews, 1991, 16, 65-82.	9.0	175
193	Expression of arylhydrocarbon hydroxylase, epoxide hydrolases, glutathione S-transferase and UDP-glucuronosyltransferases in H5-6 hepatoma cells. General Pharmacology, 1991, 22, 677-684.	0.7	11
194	Effects of RP 52028 and phenobarbital on mRNA levels of inducible and constitutive sex-specific cytochrome P450 isozymes in rat liver. Biochemical Pharmacology, 1991, 42, 1053-1060.	4.4	3
195	Expression and regulation of drug metabolizing enzymes in an immortalized rat hepatocyte cell line. Biochemical Pharmacology, 1991, 42, 1345-1351.	4.4	27
196	Oral contraceptives stimulate the excretion of clofibric acid glucuronide in women and female rats. General Pharmacology, 1991, 22, 393-397.	0.7	10
197	Enzyme mediated superoxide radical formation initiated by exogenous molecules in rat brain preparations. Toxicology and Applied Pharmacology, 1991, 110, 107-117.	2.8	29
198	In Vivo Study of the Elimination from Rat Brain of an Intracerebrally Formed Xenobiotic Metabolite, 1-Naphthyl-?-D-Glucuronide. Journal of Neurochemistry, 1991, 56, 1163-1168.	3.9	34

#	Article	IF	Citations
199	Certification of an enzyme reference material for alkaline phosphatase (CRM 371). Clinical Biochemistry, 1991, 24, 159-168.	1.9	14
200	The UDP Glucuronosyltransferase Gene Super family: Suggested Nomenclature Based on Evolutionary Divergence. DNA and Cell Biology, 1991, 10, 487-494.	1.9	267
201	Reconstituted Epidermis: A Novel Model for the Study of Drug Metabolism in Human Epidermis. Journal of Investigative Dermatology, 1990, 94, 749-752.	0.7	32
202	Production, cross reactivity, and epitope analysis of monoclonal antibodies against rat kidney gamma glutamyltransferase. Cell Biology and Toxicology, 1990, 6, 157-70.	5.3	0
203	An insertion deletion polymorphism in the signal peptide of the human apolipoprotein B gene. Human Genetics, 1990, 84, 373-5.	3.8	52
204	Blood Activity of Cu/Zn Superoxide Dismutase, Glutathione Peroxidase and Catalase in Alzheimerâ€™s Disease: A Case-Control Study. Gerontology, 1990, 36, 306-313.	2.8	84
205	Study of the sequence tagged site (STS) in the beginning of human apo A4 gene region. Nucleic Acids Research, 1990, 18, 5576-5576.	14.5	1
206	Biochemical values of immigrant groups in north-east France. Annals of Human Biology, 1990, 17, 277-287.	1.0	3
207	Differential action of thyroid hormones and chemically related compounds on the activity of UDP-glucuronosyltransferases and cytochrome P-450 isozymes in rat liver. Biochimica Et Biophysica Acta - General Subjects, 1990, 1035, 12-19.	2.4	22
208	An avidin-biotin ELISA for the measurement of mitochondrial aspartate aminotransferase in human serum. Journal of Immunological Methods, 1990, 128, 203-209.	1.4	3
209	Distribution of cytochrome p450 activities towards alkoxyresorufin derivatives in rat brain regions, subcellular fractions and isolated cerebral microvessels. Biochemical Pharmacology, 1990, 40, 2145-2151.	4.4	57
210	gamma-glutamyltransferase from human hepatoma cell lines: Purification and cell culture of HepG2 on microcarriers. Clinica Chimica Acta, 1990, 191, 221-232.	1.1	19
211	Phenobarbital inducible UDP-glucuronosyltransferase is responsible for glucuronidation of 3â€²-azido-3â€²-deoxythymidine: Characterization of the enzyme in human and rat liver microsomes. Archives of Biochemistry and Biophysics, 1990, 281, 264-270.	3.0	40
212	Novel inhibitors and substrates of bilirubin: UDP-glucuronosyltransferase Arylalkylcarboxylic acids. FEBS Journal, 1989, 183, 653-659.	0.2	25
213	Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatoma cell lines. Cell Biology and Toxicology, 1989, 5, 1-14.	5.3	45
214	Evaluation of a versatile reversed-phase high-performance liquid chromatographic system using cethexonium bromide as ion-pairing reagent for the analysis of glucuronic acid conjugates. Biomedical Applications, 1989, 493, 137-147.	1.7	8
215	Comparative induction of drug-metabolizing enzymes by hypolipidaemic compounds. General Pharmacology, 1989, 20, 407-412.	0.7	16
216	Clinical significance of a new isoform of serum alanine aminopeptidase; relationship with liver disease and alcohol consumption. Clinica Chimica Acta, 1989, 179, 23-31.	1.1	10

#	Article	IF	Citations
217	Characterization of distinct forms of cytochromes P-450, epoxide metabolizing enzymes and UDP-glucuronosyltransferases in rat skin. Biochemical Pharmacology, 1989, 38, 2187-2194.	4.4	42
218	Induction of UDP-glucuronosyltransferase isozymes in male and female rat liver microsomes by an isoquinoleine derivative (52028 RP). Biochemical Pharmacology, 1989, 38, 3634-3638.	4.4	2
219	Effect of hypolipidemic compounds on lauric acid hydroxylation and phase II enzymes. Biochemical Pharmacology, 1989, 38, 1963-1969.	4.4	13
220	Expression of rat renal gamma â€" glutamyltransferase cDNA in Escherichia coli. Biochemical and Biophysical Research Communications, 1989, 160, 1040-1046.	2.1	18
221	Cellular and Molecular Aspects of Udp-Glucuronosyltransferases. Drug Metabolism Reviews, 1989, 20, 721-731.	3.6	7
222	Î³-Glutamyltransferase reference material: An example of International cooperation. Clinica Chimica Acta, 1988, 173, 19-26.	1.1	3
223	Monoclonal antibodies to human kidney gamma-glutamyltransferase. Clinica Chimica Acta, 1988, 174, 149-161.	1.1	13
224	Effect of 1-benzylimidazole on cytochromes P-450 induction and on the activities of epoxide hydrolases and UDP-glucuronosyltransferases in rat liver. Biochemical Pharmacology, 1988, 37, 3297-3304.	4.4	24
225	A new aspect of the protective functions of the blood-brain barrier: Activities of four drug-metabolizing enzymes in isolated rat brain microvessels. Life Sciences, 1988, 42, 2515-2523.	4.3	95
226	Differential induction profile of drug-metabolizing enzymes after treatment with hypolipidaemic agents. Xenobiotica, 1987, 17, 445-457.	1.1	25
227	Ethoxyresorufin O-deethylase activity in rat brain subcellular fractions. Neuroscience Letters, 1987, 76, 58-62.	2.1	40
228	The glucuronosyltransferases: What progress can pharmacologists expect from molecular biology and cellular enzymology?. Biochemical Pharmacology, 1987, 36, 983-989.	4.4	67
229	Comparative study of clofibric acid and bilirubin glucuronidation in human liver microsomes. Biochemical Pharmacology, 1987, 36, 3923-3927.	4.4	26
230	Brain mitochondrial cytochrome P-450scc: Spectral and catalytic properties. Archives of Biochemistry and Biophysics, 1987, 254, 592-596.	3.0	44
231	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferases activities: use and comparison of differential inductions in some mamalian species. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1987, 87, 513-522.	0.2	1
232	In vitro evaluation of glucuronidation of monohydroxylated aglycones related to quantum chemically-calculated parameters. European Journal of Medicinal Chemistry, 1987, 22, 393-402.	5.5	6
233	ELISA of 6-beta-hydroxycortisol in human urine: Diurnal variations and effects of antiepileptic therapy. Clinica Chimica Acta, 1986, 157, 267-276.	1.1	33
234	Stereospecific induction of rat liver bilirubin UDPglucuronosyltransferase and lauric acid 12-hydroxylation by the isomers of 2-phenylpropionic acid. Biochimica Et Biophysica Acta - General Subjects, 1986, 882, 469-472.	2.4	11

#	Article	IF	Citations
235	Kinetic constant determination of liver microsomal and purified UDP-glucuronosyltransferase after phenobarbital and 3-methylcholanthrene treatments in rats. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1986, 83, 127-131.	0.2	5
236	Modulation of UDPGlucuronosyltransferase Activity in Rats by Dietary Lipids. Journal of Nutrition, 1986, 116, 2034-2043.	2.9	34
237	Identification of gamma-glutamyltransferase in rat liver plasma membranes after two-dimensional electrophoresis. Electrophoresis, 1986, 7, 83-88.	2.4	11
238	Multiple forms of serum aminopeptidases separated by micro two-dimensional electrophoresis under non-denaturing conditions. Electrophoresis, 1986, 7, 471-475.	2.4	12
239	Immobilization of pig liver microsomes. Applied Biochemistry and Biotechnology, 1986, 12, 199-213.	2.9	13
240	Covalent attachment of epoxide hydrolase to dextran. Enzyme and Microbial Technology, 1985, 7, 66-72.	3.2	17
241	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase activities. Biochemical Pharmacology, 1985, 34, 2235-2249.	4.4	69
242	Variations in sialic acid content of gamma-glutamyltransferase: a consequence for immunochemical determinations?. Clinica Chimica Acta, 1985, 148, 21-30.	1.1	3
243	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase(s) activities: Comparison between human and mammalian species activities. Chemico-Biological Interactions, 1984, 52, 173-184.	4.0	38
244	Inhibition studies of microsomal UDP-glucuronosyltransferase activities by furosemide and salicylamide. Pharmacological Research Communications, 1984, 16, 227-241.	0.2	16
245	Structural changes of liver microsomes in rat during neonatal life: Influence on the glucuronidation rates of various substrates. Biochemical and Biophysical Research Communications, 1984, 119, 29-34.	2.1	11
246	UDP-glucuronosyltransferase activities. Biochemical Pharmacology, 1983, 32, 953-955.	4.4	208
247	Plasma lecithin:cholesterol acyltransferase â€" reference values and effects of xenobiotics. Clinica Chimica Acta, 1983, 133, 85-96.	1.1	88
248	Differential toxicity of aflatoxin B1 in male and female rats: Relationship with hepatic drug-metabolizing enzymes. Biochemical Pharmacology, 1982, 31, 3057-3062.	4.4	33
249	Phenobarbital Induction of Cytochrome P-450 and UDPGlucuronosyltransferase in Rabbit Liver Plasma Membranes. Enzyme, 1982, 28, 41-47.	0.7	16
250	Effect of Chronic Ethanol Administration on Gamma-Glutamyltransferase Activities in Plasma and in Hepatic Plasma Membranes of Male and Female Rats. Enzyme, 1982, 28, 251-257.	0.7	24
251	Measurement of plasma gamma-glutamyltransferase in clinical chemistry: kinetic basis and standardisation propositions. Clinica Chimica Acta, 1981, 112, 187-195.	1.1	19
252	UDP-glucuronosyltransferase activities in human liver microsomes and in some laboratory animal species. Biochemical Pharmacology, 1981, 30, 2507-2510.	4.4	11

#	Article	IF	Citations
253	Stereochemical heterogeneity of hepatic UDP-glucuronosyltransferase activity in rat liver microsomes. Biochemical Pharmacology, 1981, 30, 1457-1461.	4.4	61
254	Gamma-glutamyltransferase activity of liver plasma membranes in phenobarbital â€" Treated rabbits. Pharmacological Research Communications, 1981, 13, 909-919.	0.2	9
255	Some kinetic properties of Î³-glutamyltransferase from rabbi liver. Biochimica Et Biophysica Acta - Biomembranes, 1981, 658, 220-231.	2.6	9
256	Î³-Glytamyltransferase of rabbit liver: Kinetic study of phenobarbital induction and in vitro solubilization by bile salts. Toxicology and Applied Pharmacology, 1980, 55, 1-7.	2.8	28
257	Influence of three inducers on rabbit gamma-glutamyltransferase. Pharmacological Research Communications, 1980, 12, 557-565.	0.2	8
258	Automated quantification of bone and liver alkaline phosphatase isoenzymes of human serum. Clinica Chimica Acta, 1980, 107, 203-210.	1.1	11
259	Hepatic membrane gamma-glutamyltransferase solubilization facilitated after administration of phenobarbital. Pharmacological Research Communications, 1979, 11, 211-220.	0.2	11
260	Protein and enzyme release from human leukocytes: Influence of phenothiazine derivatives. Chemico-Biological Interactions, 1977, 19, 173-183.	4.0	14
261	Competitive inhibition of glucuronidation by p-hydroxyphenyl hydantoin. Biochemical Pharmacology, 1975, 24, 152-154.	4.4	2